Woodstock Corp boosted its stake in Abbott Laboratories (NYSE:ABT) by 0.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 118,776 shares of the healthcare product maker’s stock after acquiring an additional 403 shares during the quarter. Woodstock Corp’s holdings in Abbott Laboratories were worth $5,774,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Atwood & Palmer Inc. lifted its position in Abbott Laboratories by 157.5% in the 1st quarter. Atwood & Palmer Inc. now owns 3,270 shares of the healthcare product maker’s stock valued at $145,000 after acquiring an additional 2,000 shares in the last quarter. Independent Portfolio Consultants Inc. lifted its position in Abbott Laboratories by 9.3% in the 1st quarter. Independent Portfolio Consultants Inc. now owns 3,420 shares of the healthcare product maker’s stock valued at $152,000 after acquiring an additional 292 shares in the last quarter. Farmers National Bank lifted its position in Abbott Laboratories by 1.5% in the 1st quarter. Farmers National Bank now owns 3,568 shares of the healthcare product maker’s stock valued at $158,000 after acquiring an additional 52 shares in the last quarter. Advantage Investment Management LLC lifted its position in Abbott Laboratories by 17.3% in the 1st quarter. Advantage Investment Management LLC now owns 3,674 shares of the healthcare product maker’s stock valued at $163,000 after acquiring an additional 543 shares in the last quarter. Finally, Delta Asset Management LLC TN lifted its position in Abbott Laboratories by 1.3% in the 1st quarter. Delta Asset Management LLC TN now owns 3,996 shares of the healthcare product maker’s stock valued at $178,000 after acquiring an additional 51 shares in the last quarter. 71.50% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the firm’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $52.95, for a total transaction of $3,307,257.00. Following the transaction, the insider now directly owns 113,426 shares of the company’s stock, valued at $6,005,906.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stephen R. Fussell sold 196,550 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total transaction of $9,729,225.00. Following the transaction, the insider now directly owns 221,488 shares in the company, valued at $10,963,656. The disclosure for this sale can be found here. Insiders have sold 333,310 shares of company stock worth $16,857,255 over the last three months. 0.76% of the stock is owned by insiders.

Abbott Laboratories (NYSE:ABT) traded up 1.169% on Thursday, hitting $54.975. 2,511,748 shares of the stock traded hands. The stock has a 50 day moving average of $51.40 and a 200 day moving average of $47.64. Abbott Laboratories has a 52 week low of $37.38 and a 52 week high of $54.98. The firm has a market capitalization of $95.52 billion, a PE ratio of 76.996 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The company had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. During the same period last year, the firm earned $0.55 earnings per share. The firm’s revenue was up 24.5% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post $2.49 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be given a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.95%. The ex-dividend date is Thursday, October 12th. Abbott Laboratories’s payout ratio is currently 149.30%.

Several equities research analysts recently commented on the stock. Citigroup Inc. began coverage on shares of Abbott Laboratories in a research report on Thursday, August 17th. They issued a “neutral” rating and a $53.00 price objective on the stock. Jefferies Group LLC reissued a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a research report on Friday, June 16th. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Friday, September 22nd. Barclays PLC boosted their price target on shares of Abbott Laboratories from $57.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, September 28th. Finally, BTIG Research began coverage on shares of Abbott Laboratories in a research report on Wednesday, June 21st. They set a “buy” rating and a $56.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $54.40.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/woodstock-corp-boosts-position-in-abbott-laboratories-abt/1610895.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.